Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Neuropharmacology. 2017 May 29;123:159–174. doi: 10.1016/j.neuropharm.2017.05.030

Figure 2.

Figure 2

Tyrosine (TYR) effects on catecholamine metabolites levels in vivo. TYR (31.75 – 1000 μM) was administered into the medial prefrontal cortex (MPFC) or striatum by reverse microdialysis. Time course of DOPAC during administration of L-TYR 250 μM within (A) MPFC or (B) striatum. DOPAC in MPFC (C) or striatum (D) after 3.0 h of vehicle (VEH) or TYR. HVA in MPFC (E) or striatum (F) after 3.0 h of VEH or TYR. MHPG in MPFC (G) after 3.0 h of VEH or TYR. Significantly different from baseline: * p < 0.05, ** p < 0.01, *** p < 0.001. Significantly different from VEH-treated group, † p < 0.01, †† p < 0.001. Mean ± SEM, n = 5/group.